Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs ATELVIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Treatment of osteoporosis in postmenopausal women,Treatment of osteoporosis in men at high risk of fracture,Treatment and prevention of glucocorticoid-induced osteoporosis,Off-label: Paget's disease of bone
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
35 mg orally once weekly on the same day each week, taken with at least 240 m L of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is approximately 10 days due to prolonged bone binding and slow release; clinical suppression of bone resorption persists for weeks after discontinuation.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Risedronate is not metabolized and is excreted unchanged primarily by the kidneys (<5% metabolized). No cytochrome P450 enzymes involved.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 50% of absorbed dose excreted renally unchanged; remainder eliminated via biliary/fecal routes. Renal clearance correlates with creatinine clearance.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 99% bound to plasma proteins, primarily albumin.
4-6 L/kg; large Vd indicates extensive tissue distribution
Mean Vd is 6.2 L/kg (range 4-10 L/kg), indicating extensive distribution into bone and soft tissues.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral bioavailability is approximately 0.7% (range 0.5-1.0%) under fasting conditions; food and calcium-containing beverages significantly reduce absorption.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Contraindicated in patients with Cr Cl <15 m L/min. No dose adjustment required for Cr Cl ≥15 m L/min. For Cr Cl 15-30 m L/min, use with caution due to limited data.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use caution.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Not approved for use in pediatric patients; safety and efficacy not established in children.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No specific dose adjustment required. Consider potential renal impairment (assess Cr Cl) and increased risk of gastrointestinal adverse effects. Ensure adequate calcium and vitamin D intake.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
No FDA black box warning.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypocalcemia must be corrected before therapy initiation,Severe renal impairment (Cr Cl <30 m L/min): not recommended,Osteonecrosis of the jaw (ONJ) with invasive dental procedures,Atypical femur fractures with long-term use,Upper gastrointestinal adverse events (e.g., esophagitis, ulcers) if taken incorrectly,Hypersensitivity reactions including angioedema
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypocalcemia,Creatinine clearance <30 m L/min,Inability to stand or sit upright for at least 30 minutes,History of esophageal disorders (e.g., stricture, achalasia)
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Food, beverages (except plain water), and calcium supplements reduce absorption. Avoid any food or drink for at least 30 minutes after dosing. Do not take with mineral water, coffee, tea, juice, or dairy products. Calcium, iron, magnesium, or aluminum-containing antacids should be taken at a different time of day.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Category C: In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. During first trimester, theoretical risk of skeletal formation interference. Second/third trimester: Potential for maternal hypocalcemia affecting fetal bone development. No adequate human studies. Risk cannot be excluded.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Unknown: Excretion in human milk is unknown but likely low due to high protein binding and short half-life. M/P ratio not established. Use with caution in breastfeeding due to potential for bone growth suppression in infants; alternatives preferred.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No formal dose adjustments studied. Pregnancy may increase bone turnover and renal clearance, but data insufficient to recommend dose change. Use lowest effective dose only if clearly needed. Avoid during pregnancy unless benefit outweighs risk.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
ATELVIA (risedronate) is a bisphosphonate for osteoporosis. Must be taken on an empty stomach with plain water only, at least 30 minutes before first food, drink, or other medication. Avoid in severe renal impairment (Cr Cl <30 m L/min). Monitor for hypocalcemia before initiation. Advise patients to remain upright for 30 minutes post-dose to reduce esophageal irritation.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take ATELVIA first thing in the morning, at least 30 minutes before any food, drink, or other medications.,Swallow the tablet whole with a full glass (6-8 oz) of plain water only; do not use mineral water, coffee, tea, or juice.,Do not chew, crush, or suck the tablet; remain upright (sitting or standing) for at least 30 minutes after taking.,If you miss a dose, skip it and take the next dose the following morning; do not take two doses on the same day.,Report symptoms of esophageal irritation such as difficulty or pain with swallowing, chest pain, or heartburn.,Ensure adequate intake of calcium and vitamin D as directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs ATELVIA, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. ATELVIA is a Bisphosphonate that works by Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and ATELVIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of ATELVIA is: 35 mg orally once weekly on the same day each week, taken with at least 240 m L of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and ATELVIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. ATELVIA is classified as Category C. Category C: In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. During first trimester, theoretical risk of skeletal formation interference. Second. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.